Home Global Market Rovi seals 10-year Moderna deal extension to manufacture mRNA drugs

Rovi seals 10-year Moderna deal extension to manufacture mRNA drugs

by admin
0 comment

Summary :

Spain’s Rovi (ROVI.MC) has agreed a 10-year extension to its deal with Moderna (MRNA.O) to manufacture future drugs developed with the mRNA technology used for the U.S. company’s coronavirus vaccine.


The logo of Spanish pharmaceutical firm Rovi, in charge of the “fill and finish” final stage of manufacturing for Moderna’s COVID-19 vaccine, is seen outside their lab in San Sebastian de los Reyes, Spain

The deal includes new investment to expand capacity at Rovi’s plants, the company said without disclosing the amount of investment.

The deeal keeps Rovi, which which manufactures and conditions drugs on behalf of other laboratories, as a crucial link in the development of the mRNA technology that was widely used for the first time in vaccines against COVID -19 and could be the basis for future treatments.’

Rovi’s partnership with Moderna to manufacture its COVID-19 vaccine has been a boon for the Spanish business, which doubled and tripled profit and revenue respectively in the first nine months of last year from the same period a year earlier.


For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:

Website : https://www.chemrobotics.com/ (Agrochemical Databases)

Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Our Company

ChemRobotics is a global Scientific, Technical & Business data intelligence company, especially in the field of Pharmaceutical, Agrochemical, Veterinary and Fine Chemical.

ChemRobotics Times

Subscribe ChemRobotics for the latest updates in the Pharmaceutical, Agrochemical, Veterinary, and Fine Chemical Industries

Laest News

ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved. 

Designed and Developed by Ample eBusiness